Biotechnology - , ,
Melbourne-based Broadvector Limited (Broadvector) is an Australian biotechnology company that focuses on conditions of the ageing population.This demographic is the fastest growing market in society as life expectancies increase and governments are seeking more cost effective treatments. Broadvector's projects have the potential to provide improved health solutions for existing unmet medical needs in this sector.Broadvector is developing therapies for the treatment of early stage prostate cancer and aseptic prosthetic loosening (e.g. in hip replacements) - in each case using gene directed enzyme-prodrug therapies ('GDEPT'). GDEPT is a sophisticated site-specific drug delivery system that enables drugs of high potency to be made available to target tissues, without having to circulate through the body first.Additionally, the Company's technology platform has a wide-ranging capability in developing vaccines.For further information please contact:info@broadvector.com.au
Amazon AWS